Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement

190
Anderson, KarenArizona State University

No coordinating investigator defined.

Broad based screen of possible biomarkers. p53 is included here. ALG10, ATF3, ATP6AP1, BDNF, BMX, C15orf48, CTBP1, DBT, EIF3E, FRS3, BAT4, GPR157, HOXD1, MYOZ2, PDCD6IP, RAB5A, RAC3, SELL, SERPINH1, SF3A1, SLC33A1, SOX2, TFCP2, TRIM32, UBAP1, ZMYM6, ZNF510
Proteomics
Breast and Gynecologic Cancers Research

The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody biomarkers in breast, prostate, and ovarian cancer. P53-specific gene mutations are frequent in multiple cancer types. Of the common solid tumors, p53 mutations have been identified in 50% of lung and ovarian cancers, 45% of colon cancers, 20% of breast cancers, and 10-30% of prostate cancers (The p53 Mutation Handbook, T. Soussi, http://p53/free/fr). The most common mutations vary from cancer to cancer, with 50 point mutations covering the 10 most common mutations for all major solid tumors

1.B. Project Objectives Aim 1: Generation of NAPPA protein microarrays expressing the fifty most common p53 point mutations for solid tumors as well as deletion constructs of p53. Aim 2: Identify p53 mutation-specific antibodies in a test set of breast, prostate, and ovarian cancer patient sera. a.   Using test sera from patients with prostate, ovarian, and breast cancers, identify patient sera that contain anti-p53 antibodies. b.   Using p53-antibody-positive sera from patients, screen the p53 mutation microarray to identify mutation-specific and domain-specific antibodies c.   Using p53-antibody-negative sera from patients, screen the p53 mutation microarray to identify mutation-specific antibodies d.   Determine the sensitivity and specificity of individual antibodies that distinguish patient sera from normal sera. e.   Determine if mutation-specific antibodies can distinguish tumor types.
Various including quantile regression, Fishers exact, binomial proportion and others. The methods are not yet fixed because we are still in discovery.

No datasets are currently associated with this protocol.


Announcement 7/2/2018

The 33rd EDRN Steering Committee Meeting is from September 5-6, 2018 in Boston, MA. Please click here for meeting registration and hotel information.

Announcement 6/1/2018

Dr. Sudhir Srivastava was honored with the 2017 Human Proteome Organization (HUPO) Award for a Distinguished Scientist in Clinical and Translational Proteomics. Please join us in congratulating him on his accomplishments and contributions. The awards were presented at HUPO 2017 in Dublin, Ireland and the winners were present to provide a small talk during the Awards Ceremony and HUPO Lectures.